Today on Outsourcing-Pharma.com   Extra breathing space for epinephrine MDI ban PRA's profits will soon be private Celesio sees profits drag AMRI continues growth Preclinical services news in brief

Related Industry News   Icahn invests in Genzyme, prompts takeover rumours Stem cell breakthrough avoids the embryo controversy Ventana reluctantly opens up to Roche in a bid to boost offer Practice run for pharma RFID

Breaking News on Outsourcing Pharma
Daily  Thursday 15 November 2007		Forward to a colleague

	Technical / White Paper Benefits of integrating human tissue research in drug discovery The benefits of integrating human tissue research into drug discovery and development programs are in the confidence that they provide in the selection of the NCEs most likely to succeed in the clinic, and doing this in the most financially efficient way... Click Here Access Full Stories Extra breathing space for epinephrine MDI ban The US Food and Drug Administration (FDA) has given stakeholders an extra month to get their views in on scrapping epinephrine inhalers containing CFCs... Read PRA's profits will soon be private PRA International continues to see its profits ebb away but will soon face less financial scrutiny as it nears a handover of ownership into private hands. ... Read Celesio sees profits drag Celesio fingerpointed two 'extraordinary items' in its dominant Wholesale division for the drag on company profits during the third quarter... Read AMRI continues growth Albany Molecular Research Inc (AMRI) recently turned in Q3 results, posting figures buoyed by continued demand for its pharmaceutical development services... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, news has emerged involving GATC Biotech, NextGen Sciences and Genedata... Read
	All News Headlines for: November | October | September
	Product Brochure Baxter's contract services case study Baxter's contract services case study details the expedited transfer of a commercial launched lyophilized drug to a new production site. Their team designed solutions resulting in cost savings, yield improvement and cycle optimization... Click Here
	Related Industry News Icahn invests in Genzyme, prompts takeover rumours The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover... Read Stem cell breakthrough avoids the embryo controversy US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read Ventana reluctantly opens up to Roche in a bid to boost offer In the latest twist in Roche's fight to acquire diagnostics expert Ventana, the companies have signed a confidentiality agreement that will enable the pharma giant access to Ventana's books... Read Practice run for pharma RFID IBM has teamed up with RFID specialist Tagsys to offer pharmaceutical manufacturers a chance to have a practice run implementing their RFID track and trace technology ahead of new legal requirements coming into... Read Weekly Comment Pharma must 'reinvent' itself to survive With IMS Health's annual forecast for the pharma industry predicting slower approvals, more black box warnings and the continuation of the 'wave of genericization,' the shift by pharma firms to refocus and reinvent themselves will need to move on apace in order to secure their position in a changing market. Read Previous Headlines eClinical news in Brief Outsourcing-Pharma tracks the latest eClinical movements, featuring Phase Forward, Nextrials, Octagon and Omnicare... Read Pfizer, Nektar agreement not so sweet after all? Pfizer yesterday announced a multi-million dollar pay-off to ex-partner Nektar Therapeutics, but the details of the deal reveal not only Nektar's concerns for its future, but also that Pfizer is still keeping its... Read Evotec's metamorphosis erodes profit Evotec's bid to distance itself from being a services business and eventually morph into a fully fledged pharma company has been felt on the company's balance sheet during the third quarter... Read BioCryst clinical trials debacle highlights protocol perils BioCryst's recent clinical trials debacle highlights the importance of the robust and realistic design of, and careful adherence to, a drug trial protocol... Read NPIL to trim ex-Pfizer site NPIL Pharma last week told workers at its former Pfizer plant in Morpeth, UK that the company is considering hiving off jobs in a bid to maintain the site's viability... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analytical testing, QC Bulk ingredients Contract sales & marketing Data management Drug delivery, formulation Fill & finish, packaging Phase I-II Phase III-IV Preclinical Product & Supplier News - Contract Manufacturing Regulatory affairs Supply chain, logistics Validation services

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com